SCHEMBL3005463

SCHEMBL3005463

CC(C)c1cc(C(C)C)c(S(=O)(=O)N2CCN(c3nc(Cc4ccc(Cl)cc4Cl)cs3)CC2)c(C(C)C)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP4 P15090 2/20 0.43
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
DPP8 Q6V1X1 1/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
PIK3CD O00329 1/20 0.36
PIK3CA P42336 1/20 0.36
PIK3CB P42338 1/20 0.36
PIK3CG P48736 1/20 0.36
OGA O60502 2/20 0.36
GAA P10253 1/20 0.36
LMNA P02545 2/20 0.35
MAPK1 P28482 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3006975 0.91 FABP4 (0.42) FABP4PSEN1PSEN2APH1BNCSTN
SCHEMBL3652634 0.91 MAPT (0.37) FABP4MAPTALDH1A1LMNAKMT2A
SCHEMBL3650838 0.88 FABP4 (0.38) FABP4PSEN1PSEN2APH1BNCSTN
SCHEMBL3016316 0.87 FABP4 (0.37) FABP4PSEN1PSEN2APH1BNCSTN
SCHEMBL3011668 0.86 DPP8 (0.41) FABP4DPP8MAPTALDH1A1NPC1
SCHEMBL3011364 0.86 LMNA (0.38) FABP4DPP8ALDH1A1PIK3CDPIK3CA
SCHEMBL3014217 0.86 CACNA1G (0.39) FABP4PSEN1PSEN2APH1BNCSTN
SCHEMBL3645260 0.85 ALDH1A1 (0.42) FABP4MAPTALDH1A1GAALMNA
SCHEMBL3015626 0.85 MEN1 (0.44) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3019563 0.85 ALDH1A1 (0.38) FABP4DPP8MAPTALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA FABP4 3254/4885PSEN1 14/4885PSEN2 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.